Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma

2017-06-28 04:38:21 | BioPortfolio


Prospective, multicenter, observational registry of myeloma patients undergoing hematopoietic progenitor cell mobilization for upfront autologous transplantation.


High dose therapy (HDT) and autologous hematopoietic cell transplantation (autoHCT) is considered standard therapy for younger, transplant eligible multiple myeloma (MM) patients. Mobilization of peripheral blood progenitor cells (PBPC) for HDT and autoHCT can be accomplished by using cytokines, most commonly granulocyte-colony stimulating factor (G-CSF), either alone or in combination with chemotherapy or plerixafor.

Limitations of cytokine-only mobilization in myeloma:

There is little consensus about the optimal method for PBPC mobilization in patients with MM, although there is a growing recognition of suboptimal mobilization outcomes of certain subgroups of myeloma patients mobilized with G-CSF alone. Within this context, the adverse impact of prior lenalidomide therapy on PBPC mobilization is well documented; with up to 40% of MM patients treated with lenalidomide-based induction chemotherapies not collecting ≥2 x 106 CD34+ cells/kg when mobilized with G-CSF alone.

Chemomobilization in myeloma:

In contrast, mobilization with chemotherapy (mostly cyclophosphamide) in addition to G-CSF has been shown to improve PBPC collection yield and reduce mobilization failure rates in comparison to G-CSF alone. Limited retrospective data suggest that cyclophosphamide may overcome the effects of prior lenalidomide exposure on PBPC mobilization in MM patients. Cyclophosphamide doses employed for mobilization of PBPC in MM patients in most reports have ranged from 1 gm/m2 up to 7 gm/m2. Several studies have assessed the relative impact of cyclophosphamide dose-intensity on PBPC mobilization in myeloma patients treated with conventional chemotherapy regimens. In general PBPC mobilization with high-dose cyclophosphamide (HD-CY) (7 gm/m2) plus G-CSF was found to be significantly more toxic, when compared to intermediate-dose cyclophosphamide (ID-CY) (3-4 gm/m2) and G-CSF, without any convincing evidence of superior efficacy. Studies comparing mobilization with ID-CY plus G-CSF with low-dose cyclophosphamide (LD-CY) (1-2 gm/m2) plus G-CSF, reported higher total CD34+ cell yield with ID-CY, but at the cost of higher toxicity. However, no significant difference in mobilization failure rates between the ID- and LD-CY mobilization has been reported. But these data might not be applicable to MM treated in the era of novel agents. Hamadani et al. compared the efficacy and toxicity of PBPC mobilization with G-CSF and either ID-CY or LD-CY, in MM patients receiving only novel induction regimens, and reported a more robust PBPC mobilization and significantly reduced the rates of mobilization failure with ID-CY in MM patients receiving modern inductions. Within the context of stem cell mobilization in MM patients treated with novel inductions, it appears that ID-CY and G-CSF may have a favorable risk/benefit ratio and can be considered a regimen with an optimal dose-intensity in order to assess the efficacy of novel mobilization regimens against cyclophosphamide-based mobilizing strategies. But these single center observations merit confirmation in large, multicenter datasets.

Plerixafor-based mobilization in myeloma:

Plerixafor is a small molecule that inhibits chemokine stromal cell derived factor 1-alpha from binding to CXC chemokine receptor 4, resulting in increased hematopoietic stem and progenitor cell migration into peripheral blood circulation. Plerixafor use in combination with G-CSF has resulted in significant improvements in the mobilization outcomes of MM patients. Despite the promising results of plerixafor and G-CSF for PBPC mobilization, the use of chemotherapy-based mobilization regimens remain standard practice in many transplant centers, driven in part due the costs associated with plerixafor based strategies.

Chemomobilization vs. Plerixafor-based mobilization in myeloma:

No randomized trials comparing chemomobilization vs. plerixafor plus G-CSF in patients with myeloma have been published. While a few retrospective studies have reported on the relative efficacy of cyclophosphamide-based mobilization against plerixafor and G-CSF, they included patients receiving either LD-CY or doses above 4mg/m2, contained patients with non-Hodgkin lymphoma (NHL), and likely included MM patients receiving conventional induction regimens. Awan et al. retrospectively compared that efficacy, toxicity and cost of PBPC mobilization with G-CSF and either ID-CY or plerixafor, in MM patients receiving only novel induction regimens. Compared to plerixafor, ID-CY use was associated with higher median peak peripheral blood CD34+ cell count (68/µL vs. 160/µL, p<0.001), and CD34+ cell yield on day 1 of collection (6.9 x 106/kg vs. 11.7 x 106/kg, p=<0.001). No patients in either group had mobilization failure. The total CD34+ cell yield was significantly higher in the ID-CY patients (median collection 16.6 x 106 cells/kg vs. 11.6 x 106 cells/kg; p-value <0.001). Mobilization with ID-CY was associated with significantly more frequent episodes of febrile neutropenia (16.3% vs. 0%; p=0.02), higher use of intravenous antibiotics (16.3% vs. 3%; p=0.03), transfusion support and need for hospitalizations (p=0.02). The average total cost of mobilization in the plerixafor group was significantly higher compared to the ID-CY group ($28,980 vs. $22,504.8; p-value=0.001). This study showed lower mobilization costs but greater toxicity with chemotherapy based mobilization in MM. The limitations of the analysis include small sample size and retrospective nature. Of note LD-CY in a different study was shown to be inferior to plerixafor in terms of PBPC mobilization efficacy and collection failure rates.

As needed or Just-in-time Plerixafor:

As noted previously, plerixafor combined with G-CSF provides superior mobilization outcomes in MM and NHL compared to G-CSF alone. It has also been shown to be an effective salvage option for patients failing to collect adequate CD34+ cells with G-CSF alone or chemomobilization [24-26]. However, the high cost of plerixafor has limited its routine use in HPC mobilization. Risk-adapted algorithms have been developed in several institutions to rescue patients at high-risk for mobilization failure and restrict plerixafor use to curtail mobilization costs. Veltri et al. recently reported a single institution comparative analysis of patients with MM and lymphoma who underwent G-CSF mobilization, with plerixafor used either routinely or as needed in patients at risk for mobilization failure. This analysis showed no mobilization failure events with either administering plerixafor routinely to all patients vs. by using a JIT approach, but showed that JIT method was associated with significantly lower collection costs.

While it is clear that PBPC mobilization has been a subject of several reports, including a recent registry analysis, these reports are limited by their retrospective nature, small sample size, heterogeneity of patient population and often missing information on healthcare resource utilization. In the current large, multicenter, observational study the investigators intend to collect detailed information regarding patient, disease, mobilization and healthcare utilization characteristic in a prospective fashion. This prospective, mobilization, registry dataset would then be used to evaluate efficacy of various mobilization regimens, their cost, associated healthcare resource utilization and impact on post transplantation outcomes.

Study Design


Multiple Myeloma


Autologous hematopoietic cell transplant


Center for International Blood and Marrow Transplant Research
United States


Active, not recruiting


Medical College of Wisconsin

Results (where available)

View Results


Published on BioPortfolio: 2017-06-28T04:38:21-0400

Clinical Trials [4683 Associated Clinical Trials listed on BioPortfolio]

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. An autologous stem cell ...

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma

To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.

Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

The purpose of this study is to learn more about ways to prevent or delay relapse of multiple myeloma (MM). This study will determine the best dosing schedule of LBH589 maintenance therapy...

Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)

The purpose of this study is to test what effects (good and bad) a new cancer vaccine will have on participants and their cancer, when administered before and after their autologous hemato...

Evomela Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation (AutoSCT) for Multiple Myeloma (MM)

The goal of this clinical research study is to find the recommended dose level and dosing schedule of Evomela that can help prevent multiple myeloma from coming back in patients who are re...

PubMed Articles [22654 Associated PubMed Articles listed on BioPortfolio]

Significant Nationwide Variability exists in the Costs and in Hospital Mortality Rates in Autologous Stem Cell Transplant for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample (NIS) Database.

Autologous hematopoietic stem cell transplantation (AHCT) is the standard of care for eligible multiple myeloma (MM) patients. We aim to explore disparities in hospital cost and in-hospital mortality ...

Staging Systems for Newly Diagnosed Myeloma Patients undergoing Autologous Hematopoietic Cell Transplant: The Revised International Staging System shows the most Differentiation between Groups.

The revised International Staging System (R-ISS) and the International Myeloma Working Group 2014 (IMWG 2014) are newer staging systems used to prognosticate multiple myeloma (MM) outcomes. We hypothe...

Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma.

High-dose chemotherapy and autologous stem cell transplantation (ASCT) are integral components of the overall treatment for patients with multiple myeloma (MM) aged ≤ 65 years. The emergence of oli...

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma.

Single-cycle melphalan 200 mg/m and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free survival (PFS) and overall survival (...

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.

Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) with poor long-term survival after cytotoxic chemotherapy. Many novel drugs have revolutionized the treatm...

Medical and Biotech [MESH] Definitions

An asymptomatic and slow-growing PLASMA CELL dyscrasia characterized by presence of MYELOMA PROTEINS and clonal bone marrow plasma cells without end-organ damage (e.g., renal impairment). It is distinguished from MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE by a much higher risk of progression to symptomatic MULTIPLE MYELOMA.

A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.

Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.

Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.

A member of the myeloid leukemia factor (MLF) protein family with multiple alternatively spliced transcript variants encoding different protein isoforms. In hematopoietic cells, it is located mainly in the nucleus, and in non-hematopoietic cells, primarily in the cytoplasm with a punctate nuclear localization. MLF1 plays a role in cell cycle differentiation.

More From BioPortfolio on "Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma"

Quick Search


Relevant Topic

Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Searches Linking to this Trial